This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Type 3 CNV and anti-VEGF

Type 3 CNV and anti-VEGF
Reviewed by Saruban Pasu

1 February 2019 | Saruban Pasu | EYE - Vitreo-Retinal

The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is still uncertain and controversial. All patients were loaded with three monthly injections, with follow-on treatment on a pro re nata (PRN) regimen. Ranibizumab was given at monthly intervals, with aflibercept given at two monthly intervals. A total of 63 eyes with treatment naïve Type 3 CNV were included in this retrospective study. At baseline, there were no significant differences between the aflibercept-treated eyes (21 eyes) and ranibizumab-treated eyes (42 eyes) in terms of BCVA, central foveal thickness, lesion location, mean lesion size, presence of PED, presence of reticular pseudodrusen, or subfoveal choroidal thickness (Table 1). The mean number of injections also did not significantly differ between the groups (4.53±1.33 in the aflibercept-treated group and 4.87±1.55 in the ranibizumab-treated group; P=0.213). In total, all subjects (63 eyes) received a mean of 4.76±1.61 intravitreal injections during the 12 month study period (range: 3-10). The mean BCVA (logarithm of the minimum angle of resolution [Snellen equivalent]) of the aflibercept-treated group improved from 0.71±0.42 (20/102) to 0.54±0.39 (20/69) after 12 months (P=0.022). The BCVA of the ranibizumab-treated groups also improved similarly from 0.68±0.38 (20/95) to 0.53±0.36 (20/67) after 12 months of treatment (P=0.013). However, no significant difference was found between the drugs regarding BCVA improvement. Among all subjects, GA developed in 17 eyes (27.0%) during the 12 month follow-up. the incidence of GA development was significantly higher in The aflibercept-treated group than in the ranibizumab-treated group (P=0.045); nine eyes (42.9%) developed GA in the aflibercept-treated group, and eight eyes (19.0%) developed GA in the ranibizumab-treated group.

Intravitreal aflibercept and ranibizumab injections for Type 3 neovascularization.
Cho HJ, Hwang HJ, Kim HS, et al.
RETINA
2018;38(11):2150-8.
Share This
CONTRIBUTOR
Saruban Pasu

Moorfields Eye Hospital, London, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency